Eli Lilly nears $2B-plus deal for Kelonia to expand cancer pipeline: WSJ (LLY:NYSE)

Eli Lilly is in talks to buy Kelonia Therapeutics for $2B+, boosting its oncology pipeline with next-gen CAR-T for multiple myeloma.

You will be redirected in 10 seconds.